Polpharma to invest $62.6 mln in expansion of ChimPharm plant in KazakhstanPolpharma Group will invest $62.6 million to expand the production capacity of its subsidiary ChimPharm JSC (SANTO), a pharmaceutical plant located in Shymkent, the press service of Kazakhstan’s government said in a Monday statement.Polpharma’s investment plans were discussed during a meeting between Kazakh Prime Minister Olzhas Bektenov and Jerzy Starak, chairman of Polpharma Group supervisory board, who arrived in Astana to attend the 37th plenary session of the Foreign Investors’ Council.The expansion aims to meet market demand by increasing the production capacity of the Shymkent-based pharmaceutical plant to 2 billion units of medicines annually under the SANTO Member of Polpharma Group brand.Priority therapeutic areas for local production will focus on socially significant diseases, including tuberculosis, chronic hepatitis C, liver cirrhosis, cancer, diabetes, mental disorders, and conditions affecting the central nervous and cardiovascular systems.Following the talks, both sides reaffirmed their commitment to strengthening mutually beneficial cooperation. The prime minister instructed the Ministry of Health and the Shymkent city administration to expedite preparations for an investment agreement to build an additional modern pharmaceutical production facility on the basis of the existing pharmaceutical plant.To date, Polpharma Group, which is headquartered in Amsterdam, has invested over $130 million in ChimPharm JSC. The plant produces more than 280 generic drugs across 12 pharmacotherapeutic categories, which are also exported to Russia, Kyrgyzstan, Mongolia, Uzbekistan, Tajikistan, Turkmenistan and other countries. (ICE ALMATY)

Fonte notizia: INTERFAX